Dr. Reddy’s Laboratories Ltd and its subsidiaries have issued a voluntary recall of six lots of sapropterin dihydrochloride powder for oral solution 100 mg in the US due to discolouration in some packets, which could reduce potency. The issue was discovered during an accelerated stability test and following customer complaints.
The company said the product is used to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive phenylketonuria (PKU). The reduced efficacy of the product could lead to elevated Phe levels, potentially causing permanent neurocognitive deficits, developmental delay, and seizures in infants and children. Elevated Phe levels during pregnancy are associated with microcephaly and congenital heart disease.
The company also said it has not received any reports of adverse events related to the recall to date. The affected lots were distributed to wholesalers and retailers. The company is notifying its distributors and customers through letters and is arranging for the return of all recalled products, it said.
The shares were up by 0.31% to ₹5,972.30 at 1.35 pm on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.